MX2022006537A - Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia. - Google Patents

Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia.

Info

Publication number
MX2022006537A
MX2022006537A MX2022006537A MX2022006537A MX2022006537A MX 2022006537 A MX2022006537 A MX 2022006537A MX 2022006537 A MX2022006537 A MX 2022006537A MX 2022006537 A MX2022006537 A MX 2022006537A MX 2022006537 A MX2022006537 A MX 2022006537A
Authority
MX
Mexico
Prior art keywords
dementia
patients
sub
psychological symptoms
receptor antagonist
Prior art date
Application number
MX2022006537A
Other languages
English (en)
Inventor
Vijay Sidram Benade
Ramakrishna Nirogi
Anil Karbhari Shinde
Pradeep Jayarajan
Venkateswarlu Jasti
Renny Abraham
Veena Reballi
Rajesh Badange
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MX2022006537A publication Critical patent/MX2022006537A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención proporciona un método para tratar síntomas de comportamiento y psicológicos en pacientes con demencia que comprenden administrar una dosis 5 efectiva de antagonista receptor de-HT6 puro e inhibidor de acetilcolinesterasa y antagonista receptor de NMDA; la presente invención también se refiere a una combinación farmacéutica que comprende antagonista receptor de 5-HT6 puro e inhibidor de acetilcolinesterasa o antagonista receptor de NMDA, en particular para tratar síntomas de comportamiento y psicológicos en pacientes con demencia; la presente invención además proporciona uso de dichos compuestos en la fabricación de un medicamento, y una composición farmacéutica que comprende dichos compuestos que se pretenden para el tratamiento de trastornos aquí descritos.
MX2022006537A 2019-12-02 2020-12-02 Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia. MX2022006537A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201941049513 2019-12-02
IN201941049515 2019-12-02
PCT/IB2020/061367 WO2021111320A1 (en) 2019-12-02 2020-12-02 Methods for treating behavioral and psychological symptoms in patients with dementia

Publications (1)

Publication Number Publication Date
MX2022006537A true MX2022006537A (es) 2022-12-13

Family

ID=73857227

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006537A MX2022006537A (es) 2019-12-02 2020-12-02 Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia.

Country Status (11)

Country Link
US (1) US20230000859A1 (es)
EP (1) EP4069231A1 (es)
JP (1) JP2023510082A (es)
KR (1) KR20220110518A (es)
CN (1) CN114761008A (es)
AU (1) AU2020396396A1 (es)
BR (1) BR112022010540A2 (es)
CA (1) CA3162938A1 (es)
IL (1) IL293373A (es)
MX (1) MX2022006537A (es)
WO (1) WO2021111320A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE401307T1 (de) 2002-11-28 2008-08-15 Suven Life Sciences Ltd N-arylsulfonyl-2-substituierte indole mit affinität zum serotonin rezeptor, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
EP1902733A1 (en) * 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
RS56323B1 (sr) 2013-12-02 2017-12-29 Suven Life Sciences Ltd Proces za masovnu proizvodnju monohidrata 1-[(2-bromofenil)sulfonil]-5-metoksi-3-[(4-metil-1-piperazinil)metil]-1h-indol dimezilata
US10864191B2 (en) 2016-05-11 2020-12-15 H. Lundbeck A/S 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
WO2017199072A1 (en) * 2016-05-18 2017-11-23 Suven Life Sciences Limited Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist
RS60422B1 (sr) * 2016-05-18 2020-07-31 Suven Life Sciences Ltd Kombinacija čistih antagonista 5-ht6 receptora sa inhibitorima acetilholinesteraze
CN109152751A (zh) * 2016-05-18 2019-01-04 苏文生命科学有限公司 纯5-ht6受体拮抗剂、乙酰胆碱酯酶抑制剂和nmda受体拮抗剂的三重组合
SG11201913104QA (en) 2017-07-03 2020-01-30 Suven Life Sciences Ltd New uses of a pure 5-ht 6 receptor antagonist

Also Published As

Publication number Publication date
BR112022010540A2 (pt) 2022-08-16
KR20220110518A (ko) 2022-08-08
IL293373A (en) 2022-07-01
EP4069231A1 (en) 2022-10-12
AU2020396396A1 (en) 2022-06-16
JP2023510082A (ja) 2023-03-13
CN114761008A (zh) 2022-07-15
US20230000859A1 (en) 2023-01-05
CA3162938A1 (en) 2021-06-10
WO2021111320A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
MX2021009037A (es) Composiciones y metodos para el manejo de trastornos.
Lane et al. Comparative efficacy of chlorpromazine and meperidine with dimenhydrinate in migraine headache
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
MX2022005994A (es) Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras.
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
PH12020551425A1 (en) Rimegepant for cgrp related disorders
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
MY166890A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2014001088A (es) Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas.
MX2015002378A (es) Composicion ansiolitica, formulacion y metodo de uso.
EA202191079A1 (ru) Способы лечения синдрома ретта с применением фенфлурамина
TW200631956A (en) Azabenzoxazoles for the treatment of CNS disorders
MX2021012904A (es) Moduladores de la via de respuesta al estres integrada.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
JP2016510343A5 (es)
US20040092519A1 (en) New treatment for hot flashes
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
MX2021009082A (es) Compuestos quimicos.
MX2022006537A (es) Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia.
Shukla et al. Comparative study of tramadol and diclofenac as analgesic for postoperative pain
MX2022006535A (es) Métodos para tratar síntomas de comportamiento y psicológicos en pacientes con demencia.
Osaka et al. Emerging trends in antipsychotic and antidepressant drug development: Targeting nonmonoamine receptors and innovative mechanisms
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.